How Durable Is Functional Cure (Hepatitis B Surface Antigen Loss) in Patients With Chronic Hepatitis B Treated With Current Antivirals?

Affiliations

¹ CRC "A.M. and A. Migliavacca" Center for the Study of Liver Disease Division of Gastroenterology and Hepatology Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico Università degli Studi di Milano Milan Italy.

Editorial

Alessandro Loglio et al. Hepatol Commun. 2020.

. 2020 Jan 2;4(1):5-7.

doi: 10.1002/hep4.1476. eCollection 2020 Jan.

¹ CRC "A.M. and A. Migliavacca" Center for the Study of Liver Disease Division of Gastroenterology and Hepatology Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico Università degli Studi di Milano Milan Italy.

No abstract available

References

1. Lok AS, Zoulim F, Dusheiko G, Chan HL, Buti M, Ghany MG, et al. Durability of hepatitis B surface antigen loss with nucleotide analogue and peginterferon therapy in patients with chronic hepatitis B. Hepatol Commun 2020. 10.1002/hep4.1436/full. - DOI - PMC - PubMed
1. Alaward AS, Auh S, Suarez D, Ghany MG. Durability of spontaneous and treatment‐related loss of hepatitis B s antigen. Clin Gastroenterol Hepatol 2019. 10.1016/j.cgh.2019.07.018. - DOI - PMC - PubMed
1. Yip TC, Wong GL, Wong VW, Tse YK, Lui GC, Lam KL, et al. Durability of hepatitis B surface antigen seroclearance in untreated and nucleos(t)ide analogue‐treated patients. J Hepatol 2018;68:63‐72. - PubMed
1. Kim GA, Lim YS, An J, Lee D, Shim JH, Kim KM, et al. HBsAg seroclearance after nucleoside analogue therapy in patients with chronic hepatitis B: clinical outcomes and durability. Gut 2014;63:1325‐1332. - PubMed
1. European Association for the Study of the Liver . EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol 2017;67:370‐398. - PubMed